Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1992 Oct;216(4):463–482. doi: 10.1097/00000658-199210000-00010

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

D L Morton 1, L J Foshag 1, D S Hoon 1, J A Nizze 1, E Famatiga 1, L A Wanek 1, C Chang 1, D G Davtyan 1, R K Gupta 1, R Elashoff 1, et al.
PMCID: PMC1242654  PMID: 1417196

Abstract

A new polyvalent melanoma cell vaccine (MCV) was administered to 136 stage IIIA and IV (American Joint Committee on Cancer) melanoma patients. Induction of cell-mediated and humoral immune responses to common melanoma-associated antigens present on autologous melanoma cells was observed in patients receiving the new MCV. This was accompanied by increased activation of tumor-infiltrating lymphocytes. Survival correlated significantly with delayed cutaneous hypersensitivity (p = 0.0066) and antibody responses to MCV (p = 0.0117). Of 40 patients with evaluable disease, nine (23%) had regressions (three complete). From our historical database of 126 stage IIIA and 1275 stage IV melanoma patients, there were no significant changes in the natural history of metastatic melanoma during the past 20 years. Univariate and multivariate analyses demonstrated prognostic significance for site of metastases (p = 0.0001) and immunotherapy with the new MCV (p = 0.0001). Overall our new MCV increased the median and 5-year survival of stage IIIA melanoma patients with regional soft tissue metastases twofold (p = 0.00024), and stage IV patients threefold (p = 0.0001) compared with previous immunotherapy and other treatments.

Full text

PDF
463

Images in this article

470FIG. 5.
on p.470
470FIG. 5.
on p.470
470FIG. 6.
on p.470
476FIG. 18.
on p.476
476FIG. 18.
on p.476
477FIG. 19.
on p.477

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmann D. L., Creagan E. T., Hahn R. G., Edmonson J. H., Bisel H. F., Schaid D. J. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer. 1989 Jan 15;63(2):224–227. doi: 10.1002/1097-0142(19890115)63:2<224::aid-cncr2820630203>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  2. Arroyo P. J., Bash J. A., Wallack M. K. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model. Cancer Immunol Immunother. 1990;31(5):305–311. doi: 10.1007/BF01740939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Balch C. M., Soong S. J., Murad T. M., Smith J. W., Maddox W. A., Durant J. R. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983 Feb;1(2):126–134. doi: 10.1200/JCO.1983.1.2.126. [DOI] [PubMed] [Google Scholar]
  4. Berd D., Maguire H. C., Jr, Mastrangelo M. J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 1986 May;46(5):2572–2577. [PubMed] [Google Scholar]
  5. Berd D., Maguire H. C., Jr, Mastrangelo M. J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 1986 May;46(5):2572–2577. [PubMed] [Google Scholar]
  6. Berd D., Murphy G., Maguire H. C., Jr, Mastrangelo M. J. Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. 1991 May 15;51(10):2731–2734. [PubMed] [Google Scholar]
  7. Berdeaux D. H., Moon T. E., Meyskens F. L., Jr Clinical-biologic patterns of metastatic melanoma and their effect on treatment. Cancer Treat Rep. 1985 Apr;69(4):397–401. [PubMed] [Google Scholar]
  8. Bystryn J. C., Oratz R., Harris M. N., Roses D. F., Golomb F. M., Speyer J. L. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer. 1988 Mar 15;61(6):1065–1070. doi: 10.1002/1097-0142(19880315)61:6<1065::aid-cncr2820610602>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  9. Cahan L. D., Irie R. F., Singh R., Cassidenti A., Paulson J. C. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7629–7633. doi: 10.1073/pnas.79.24.7629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ceuppens J., Goodwin J. Prostaglandins and the immune response to cancer (review). Anticancer Res. 1981;1(2):71–78. [PubMed] [Google Scholar]
  11. Cheresh D. A., Varki A. P., Varki N. M., Stallcup W. B., Levine J., Reisfeld R. A. A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. J Biol Chem. 1984 Jun 25;259(12):7453–7459. [PubMed] [Google Scholar]
  12. Euhus D. M., Gupta R. K., Morton D. L. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother. 1989;29(4):247–254. doi: 10.1007/BF00199212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fossati G., Taramelli D., Balsari A., Bogdanovich G., Andreola S., Parmiani G. Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes. Int J Cancer. 1984 May 15;33(5):591–597. doi: 10.1002/ijc.2910330508. [DOI] [PubMed] [Google Scholar]
  14. Golumbek P. T., Lazenby A. J., Levitsky H. I., Jaffee L. M., Karasuyama H., Baker M., Pardoll D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991 Nov 1;254(5032):713–716. doi: 10.1126/science.1948050. [DOI] [PubMed] [Google Scholar]
  15. Goodnight J. E., Jr, Moseley H. S., Eilber F. R., Sarna G., Morton D. L. Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2005–2007. [PubMed] [Google Scholar]
  16. Griswold D. E., Alessi S., Badger A. M., Poste G., Hanna N. Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J Immunol. 1984 Jun;132(6):3054–3057. [PubMed] [Google Scholar]
  17. Guerry D., 4th, Alexander M. A., Herlyn M. F., Zehngebot L. M., Mitchell K. F., Zmijewski C. M., Lusk E. J. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest. 1984 Jan;73(1):267–271. doi: 10.1172/JCI111201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gupta R. K., Morton D. L. Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. J Natl Cancer Inst. 1983 Jun;70(6):993–1004. [PubMed] [Google Scholar]
  19. Gupta R. K., Morton D. L. Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. I. Purification and development of a radioimmunoassay. J Natl Cancer Inst. 1984 Jan;72(1):67–74. doi: 10.1093/jnci/72.1.67. [DOI] [PubMed] [Google Scholar]
  20. Hayashi Y., Hoon D. S., Park M. S., Terasaki P. I., Foshag L. J., Morton D. L. Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. Cell Immunol. 1992 Feb;139(2):411–425. doi: 10.1016/0008-8749(92)90082-z. [DOI] [PubMed] [Google Scholar]
  21. Hayashi Y., Hoon D. S., Park M. S., Terasaki P. I., Morton D. L. Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A. Cancer Immunol Immunother. 1992;34(6):419–423. doi: 10.1007/BF01741754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hoon D. S., Banez M., Okun E., Morton D. L., Irie R. F. Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. Cancer Res. 1991 Apr 15;51(8):2002–2008. [PubMed] [Google Scholar]
  23. Hoon D. S., Foshag L. J., Nizze A. S., Bohman R., Morton D. L. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res. 1990 Sep 1;50(17):5358–5364. [PubMed] [Google Scholar]
  24. Hoon D. S., Korn E. L., Cochran A. J. Variations in functional immunocompetence of individual tumor-draining lymph nodes in humans. Cancer Res. 1987 Mar 15;47(6):1740–1744. [PubMed] [Google Scholar]
  25. Hoon D. S., Okun E., Banez M., Irie R. F., Morton D. L. Interleukin 4 alone and with gamma-interferon or alpha-tumor necrosis factor inhibits cell growth and modulates cell surface antigens on human renal cell carcinomas. Cancer Res. 1991 Oct 15;51(20):5687–5693. [PubMed] [Google Scholar]
  26. Hoover H. C., Jr, Surdyke M. G., Dangel R. B., Peters L. C., Hanna M. G., Jr Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer. 1985 Mar 15;55(6):1236–1243. doi: 10.1002/1097-0142(19850315)55:6<1236::aid-cncr2820550616>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  27. Irie R. F., Morton D. L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8694–8698. doi: 10.1073/pnas.83.22.8694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Jones P. C., Sze L. L., Liu P. Y., Morton D. L., Irie R. F. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst. 1981 Feb;66(2):249–254. [PubMed] [Google Scholar]
  29. Livingston P. O., Cunningham-Rundles S., Marfleet G., Gnecco C., Wong G. Y., Schiffman G., Enker W. E., Hoffman M. K. Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. J Biol Response Mod. 1987 Aug;6(4):392–403. [PubMed] [Google Scholar]
  30. Livingston P. O., Natoli E. J., Calves M. J., Stockert E., Oettgen H. F., Old L. J. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A. 1987 May;84(9):2911–2915. doi: 10.1073/pnas.84.9.2911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Mitchell M. S., Kan-Mitchell J., Kempf R. A., Harel W., Shau H. Y., Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. 1988 Oct 15;48(20):5883–5893. [PubMed] [Google Scholar]
  32. Morton D. L. Active immunotherapy against cancer: present status. Semin Oncol. 1986 Jun;13(2):180–185. [PubMed] [Google Scholar]
  33. Morton D. L., Eilber F. R., Holmes E. C., Hunt J. S., Ketcham A. S., Silverstein M. J., Sparks F. C. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974 Oct;180(4):635–643. doi: 10.1097/00000658-197410000-00029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Morton D. L., Eilber F. R., Holmes E. C., Ramming K. P. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust N Z J Surg. 1978 Feb;48(1):49–52. doi: 10.1111/j.1445-2197.1978.tb05804.x. [DOI] [PubMed] [Google Scholar]
  35. Morton D. L., Eilber F. R. Prognostic significance of cutaneous anergy for the surgical treatment of solid neoplasms. Natl Cancer Inst Monogr. 1971 Dec;34:103–108. [PubMed] [Google Scholar]
  36. Morton D. L., Foshag L. J., Nizze J. A., Gupta R. K., Famatiga E., Hoon D. S., Irie R. F. Active specific immunotherapy in malignant melanoma. Semin Surg Oncol. 1989;5(6):420–425. doi: 10.1002/ssu.2980050608. [DOI] [PubMed] [Google Scholar]
  37. Morton D. L., Joseph W. L., Ketcham A. S., Geelhoed G. W., Adkins P. C. Surgical resection and adjunctive immunotherapy for selected patients with multiple pulmonary metastases. Ann Surg. 1973 Sep;178(3):360–366. doi: 10.1097/00000658-197309000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Morton D. L., Malmgren R. A., Holmes E. C., Ketcham A. S. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery. 1968 Jul;64(1):233–240. [PubMed] [Google Scholar]
  39. Morton D., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970 Jul;68(1):158–164. [PubMed] [Google Scholar]
  40. Naito K., Pellis N. R., Kahan B. D. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide. Cancer Res. 1988 Jan 1;48(1):101–108. [PubMed] [Google Scholar]
  41. Nishimura T., Ohta S., Sato N., Togashi Y., Goto M., Hashimoto Y. Combination tumor-immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice. Int J Cancer. 1987 Aug 15;40(2):255–261. doi: 10.1002/ijc.2910400222. [DOI] [PubMed] [Google Scholar]
  42. Ravindranath M. H., Morton D. L., Irie R. F. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res. 1989 Jul 15;49(14):3891–3897. [PubMed] [Google Scholar]
  43. Ravindranath M. H., Morton D. L. Role of gangliosides in active immunotherapy with melanoma vaccine. Int Rev Immunol. 1991;7(4):303–329. doi: 10.3109/08830189109114877. [DOI] [PubMed] [Google Scholar]
  44. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  46. Roth J. A., Morton D. L., Holmes E. C. Rejection of dinitrochlorobenzene-conjugated syngeneic tumor cells by dinitrochlorobenzene-sensitized guinea pigs. J Surg Res. 1978 Jul;25(1):1–7. doi: 10.1016/0022-4804(78)90148-8. [DOI] [PubMed] [Google Scholar]
  47. Saxton R. E., Irie R. F., Ferrone S., Pellegrino M. A., Morton D. L. Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients. Int J Cancer. 1978 Mar 15;21(3):299–306. doi: 10.1002/ijc.2910210308. [DOI] [PubMed] [Google Scholar]
  48. Shibata M., Hoon D., Okun E., Morton D. Modulation of histamine type II receptors on CD8+ T cells by interleukin-2 and cimetidine. Int Arch Allergy Immunol. 1992;97(1):8–16. doi: 10.1159/000236089. [DOI] [PubMed] [Google Scholar]
  49. Sparks F. C., Silverstein M. J., Hunt J. S., Haskell C. M., Pilch Y. H., Morton D. L. Complications of BCG immunotherapy in patients with cancer. N Engl J Med. 1973 Oct 18;289(16):827–830. doi: 10.1056/NEJM197310182891603. [DOI] [PubMed] [Google Scholar]
  50. Storm F. K., Sparks F. C., Morton D. L. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion. Surg Gynecol Obstet. 1979 Jul;149(1):17–21. [PubMed] [Google Scholar]
  51. Tai T., Paulson J. C., Cahan L. D., Irie R. F. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci U S A. 1983 Sep;80(17):5392–5396. doi: 10.1073/pnas.80.17.5392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Tanigawa N., Kern D. H., Hikasa Y., Morton D. L. Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture. Cancer Res. 1982 Jun;42(6):2159–2164. [PubMed] [Google Scholar]
  53. Torisu M., Goya T., Hayashi Y., Tanaka J., Sugisaki T., Yoshida T. Electrocardiogram studies on cancer patients treated with OK-432, a streptococcal preparation with potent biological response modifier activities. J Biol Response Mod. 1989 Dec;8(6):665–675. [PubMed] [Google Scholar]
  54. Wallack M. K., McNally K. R., Leftheriotis E., Seigler H., Balch C., Wanebo H., Bartolucci A. A., Bash J. A. A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. Cancer. 1986 Feb 1;57(3):649–655. doi: 10.1002/1097-0142(19860201)57:3<649::aid-cncr2820570342>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  55. White W. B., Ballow M. Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia. N Engl J Med. 1985 Jan 24;312(4):198–202. doi: 10.1056/NEJM198501243120402. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES